Germany Becomes First EU Country to Offer Psilocybin Therapy Outside Clinical Trials

By Joseph Santiago
Utrecht, The Netherlands — August 2025

BERLIN — On a quiet street in the German capital, a small clinic is making global headlines. Inside its pale-blue therapy rooms, patients struggling with severe depression are being offered something once reserved for university labs and underground retreats: psilocybin. Not in a study, not in a trial — but as part of real-world medical care.

In a European first, the OVID Clinic Berlin and the Central Institute for Mental Health (CIMH) in Mannheim have received approval to administer psilocybin-assisted therapy outside of clinical trials. The move — part of a tightly regulated compassionate use program — marks a seismic shift in the way mental health is treated in Germany, and could ripple through the continent.

“This is the beginning of a new era for psychiatric care in Europe,” said Dr. Martin von Berlepsch, clinical director at OVID. “We’re not just studying this anymore — we’re helping people now.”

🌟 A Turning Point for Psychedelic Medicine

For decades, psilocybin — the active ingredient in psychedelic ‘magic mushrooms’ — was lumped with LSD and MDMA under restrictive drug laws, dismissed by regulators and feared by psychiatrists. But a wave of new research has turned the tide.

Studies at institutions like Johns Hopkins, Imperial College London, and Zurich University have shown that a single high-dose psilocybin session, paired with therapy, can lead to dramatic reductions in depression, anxiety, PTSD, and even end-of-life distress.

Until now, these sessions were only accessible in research studies or retreats operating in legal gray zones. Germany’s decision to greenlight psilocybin therapy for patients outside of trials is unprecedented.

“It’s comparable to the moment medical cannabis first became available in pharmacies,” said Dr. Anja Tietz, a neuropharmacologist at Charité Berlin. “Only here, the science is arguably even stronger.”

💊 The Details: What’s Actually Happening?

The new program is not a blanket legalization — far from it. Under the compassionate use clause, psilocybin is available only to patients with treatment-resistant depression (TRD) who have failed at least two prior treatments. Fewer than 50 patients are expected to be enrolled in the first year.

Here’s how it works:

  • Patients are referred by a licensed psychiatrist.
  • After screening and medical review, they undergo 2–3 preparatory sessions with a trained therapist.
  • A single dose of psilocybin — provided as PEX010, a botanical extract from Filament Health — is administered in a controlled clinical setting.
  • Sessions are supervised by both a physician and a licensed psychotherapist, followed by structured integration sessions.

While there has been speculation around therapy costs ranging from €3,500 to €5,000, Filament Health has announced that it is providing PEX010 free of charge under this program, and full treatment pricing has not been publicly confirmed.

“We’re doing everything by the book: trained staff, medical protocols, safety systems in place,” said Dr. von Berlepsch. “This isn’t a trip — it’s therapy.”

🧠 The Science Behind the Experience

Psilocybin works by converting into psilocin, which binds to serotonin receptors in the brain. This action temporarily reduces activity in the default mode network — the part of the brain responsible for self-criticism, rumination, and rigid thought patterns often linked to depression.

In many patients, the result is described as a “reset” — a brief but profound window where old mental habits dissolve and new insights arise.

“I felt like I could see my depression from outside myself,” said one patient who received early access. “It wasn’t gone, but it didn’t own me anymore.”

If you’re exploring safe and legal alternatives, browse our full collection of psilocybin truffles at Microdose Bros.

Our truffles are 100% legal in the Netherlands and can therefore be shipped to most EU countries under the Mutual Recognition of Goods Principle of the European Commission.

Due to our high successful delivery rate (> 98%), we currently have a delivery guarantee for most orders within the EU. Have a look at our Shipping Information for full details.

Our truffles are specifically grown for microdosing in the Netherlands. Cultivated under strictly controlled conditions by experienced farmers, these premium psilocybin truffles are harvested at peak potency and processed to ensure a consistent quality in every dose.

⚖️ A Careful Balance: Hope vs. Hype

While the move has been welcomed by many mental health professionals, critics are urging caution.

Some worry about the lack of long-term data, others about the risks of misuse or commercialization. And there’s concern that rising demand could outpace therapist training, leading to uneven outcomes — or worse, unsafe practices.

“Psychedelic therapy is not a magic bullet,” warned Dr. Verena Müller, a clinical psychologist in Munich. “It can help, but only with proper preparation, guidance, and aftercare.”

Germany’s medical board has stressed that psilocybin remains a controlled substance, and that unauthorized use outside of approved programs remains illegal. The compassionate use program is time-limited and will likely end once psilocybin gains formal EU pharmaceutical approval.

🌍 A Signal to the Rest of Europe?

Germany’s program could serve as a template for other European countries, especially as the EU Medicines Agency and World Health Organization continue reviewing psychedelic compounds for potential rescheduling.

Switzerland already permits psilocybin in rare therapeutic cases. The Netherlands allows psilocybin truffles under wellness rules. Portugal, Czech Republic, and Austria are watching closely.

“The ice is cracking,” said Dr. Lisa Meier, a bioethicist at the University of Vienna. “Germany is showing what a responsible, science-based rollout can look like.”

🔮 What’s Next?

The OVID Clinic and CIMH report dozens of patient inquiries, with structured enrollment underway. Meanwhile, Filament Health is preparing for expanded trials and regulatory filings, while other pharmaceutical firms like Compass Pathways (COMP360) and Cybin (CYB003) continue Phase 3 trials across Europe.

Germany’s clinician-led model — where prescribing power lies with psychiatrists rather than regulatory case-by-case approvals — could accelerate adoption elsewhere if shown to be safe and effective.

“If this works, if we can treat people who were out of options,” said Dr. von Berlepsch, “then this won’t be a trend. It’ll be a transformation.”

Editor’s Note: The cost of therapy under Germany’s compassionate use program has not been confirmed. While early reports suggested treatment packages could range from €3,500 to €5,000, Filament Health has stated that its psilocybin product is being provided at no cost during the early rollout.

📲 Follow Microdose Bros on Social Media

Stay informed and inspired—join our community:

We share science-backed insights, community stories, and everything you need to navigate the world of microdosing with confidence. 🌱